Fulcrum Therapeutics, Inc.
$7.94
▲
7.49%
2026-04-21 06:58:01
www.fulcrumtx.com
NGM: FULC
Explore Fulcrum Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$552.12 M
Current Price
$7.94
52W High / Low
$15.74 / $2.92
Stock P/E
—
Book Value
$5.24
Dividend Yield
—
ROCE
-24%
ROE
-25.3%
Face Value
—
EPS
$-1.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
55
Beta
3.27
Debt / Equity
1.85
Current Ratio
27.4
Quick Ratio
27.4
Forward P/E
-4.71
Price / Sales
—
Enterprise Value
$156.97 M
EV / EBITDA
-1.88
EV / Revenue
—
Rating
Buy
Target Price
$19
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Niagen Bioscience, Inc. | $4.87 | 22.44 | $389.99 M | — | 16.53% | 28.35% | $14.69 / $4.16 | $0.96 |
| 2. | TransCode Therapeutics, Inc. | $8.88 | — | $8.07 M | — | -334.68% | -17.63% | $22.03 / $6.08 | $1.71 |
| 3. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 4. | Adaptive Biotechnologies Corporation | $14.58 | — | $2.23 B | — | -13.51% | -27.82% | $20.76 / $6.77 | $1.42 |
| 5. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
| 6. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 7. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -22.69 M | -21.86 M | -19.82 M | -20.4 M | -19.43 M | — |
| Net Profit | -20.33 M | -19.59 M | -17.3 M | -17.66 M | -16.57 M | — |
| EPS in Rs | -0.31 | -0.29 | -0.26 | -0.27 | -0.25 | -0.35 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 80 M | 2.81 M | 6.34 M |
| Operating Profit | -84.77 M | -19.83 M | -110.66 M | -112.13 M |
| Net Profit | -74.88 M | -9.72 M | -97.33 M | -109.87 M |
| EPS in Rs | -1.12 | -0.15 | -1.46 | -1.65 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 366.28 M | 260.72 M | 257.69 M | 226.69 M |
| Total Liabilities | 17.28 M | 17.68 M | 22.5 M | 27.74 M |
| Equity | 349 M | 243.03 M | 235.19 M | 198.94 M |
| Current Assets | 357.48 M | 249.92 M | 242.2 M | 207.52 M |
| Current Liabilities | 13.05 M | 11.04 M | 13.68 M | 16.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -60.06 M | -2.22 M | -90.97 M | -97.05 M |
| Investing CF | 30.72 M | 32.23 M | -36.69 M | 12.41 M |
| Financing CF | 168.67 M | 2.75 M | 118.12 M | 84.32 M |
| Free CF | -60.38 M | -2.5 M | -91.47 M | -99.01 M |
| Capex | -0.31 M | -0.28 M | -0.51 M | -1.96 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2752.05% | -55.77% | — | — |
| Earnings Growth % | 90.01% | 11.41% | — | — |
| Profit Margin % | -12.16% | -3470.05% | -1732.43% | — |
| Operating Margin % | -24.79% | -3945.24% | -1768.12% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -22.8% | -3867.81% | -1730.05% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.